The Nijmegen-Leiden-Amsterdam 2-tiered Care Path Study (NLA2)

February 1, 2023 updated by: Dr. A.G. (Onno) Holleboom, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

A Care Path for the Detection of Advanced NAFLD-fibrosis: the Nijmegen-Leiden-Amsterdam 2-tiered Care Path Study - the NLA2 Study

Non-alcoholic fatty liver disease (NAFLD) is a liver disease, caused by storage of fat in the liver. The most-important risk-factors are being overweight, and disorders in sugar and cholesterol handling of the body. On average does around 30% of the population worldwide have any signs of fatty liver. Most people will not get severe complaints as a result of their fatty liver. But in some of them, the fat storage will lead to hepatitis. This causes damage to the liver which can eventually lead to scarring of the liver, and in some patients to cirrhosis. This possibly can cause liver failure, liver cancer, an several complaints which reduce the quality of life. There are several tests which can help in detecting scarring of the liver. However, the scientific world still does not know well enough which test works best and if they perhaps might work better if they are used together. In this study these questions will be investigated in order to design a care path which does several tests consecutively. The goal is that this will make it possible to easily detect a severely diseased liver and that this will eventually help to detect patients earlier so they can be treated earlier and complications of the disease might be reduced. Moreover, is the goal that this study will lead to a decrease in unnecessary referrals to a hepatologist, resulting in a reduction in invasive diagnostic interventions. Hospital specialists who think that their patient might be at risk for advanced liver disease, can refer a patient to this study. Participants will go to the hospital for one study visit where several tests will be done which are designed to detect liver scarring. Depending on the results, a participant will be referred to a hepatologist for more extensive diagnostics or referred back to the referring specialist with advice for management of the disease.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Background of the study:

Non-alcoholic fatty liver disease (NAFLD) is a disease of alarmingly increasing prevalence. Progression along the NAFLD spectrum often goes unnoticed since it is often asymptomatic. Awareness among health care workers and implementation of care paths to detect progressing NAFLD stages are limited. Without clear guidance papers or robust care pathways for risk stratification, the current diagnostic approach for NAFLD is highly variable, leading to both underdiagnosis of advanced stages of disease, andunnecessary referrals for mild stages of disease. This calls for a comprehensive care path consisting of non-invasive alternatives to detect those patients with severe cases of NAFLD. Particularly the use of a sequential, two-tiered care path algorithm is promising as it has the ability to detect underlying advanced cases of fibrosis, and has previously been shown to be cost-effective. This was shown by dr. Ankur Srivastava, who designed a pathway consisting of FIB4-score and ELF-test that led to a reduction of unnecessary referrals to the hepatologist by 80%, whilst improving the detection of advanced fibrosis and cirrhosis 5- and 3-fold,respectively (8). In this study the investigation of several two-tiered sequential care path algorithms, comprised of the FIB4-score, VCTE and the ELF-test, for the detection of advanced stages of NAFLD-fibrosis is proposed: the Nijmegen-Leiden-AmsterdamNAFLD-NASH 2-tiered care path study: NLA2-study.

Objective of the study:

The aim of the study is to improve case finding of advanced cases of NAFLD (≥F3 fibrosis), whilst simultaneously reducing unnecessary referrals for mild cases (<F3 fibrosis). Additionally, the aim is to increase awareness of NAFLD, and NAFLD-related complications, and to assess the cost-effectiveness of the different proposed care paths compared to current regular care.

Study design:

This is a care innovation study, with an estimated duration of three years. The intend is to commence the study at three academic medical centres namely in Nijmegen, Leiden and Amsterdam, with the intention to include other non-academic hospitals after the initial roll-out. The study has both a prospective and a retrospective part. The prospective part consists of participants who are deemed by their treating specialist physician to be at risk of severe NASH fibrosis. Participants will be invited to attend a study visit.

This study visit will consist of, among others: anthropometric measurements, blood pressure measurement, blood sampling and VCTE. The diagnostic testing for potentially underlying advanced (≥F3) liver fibrosis consists of the FIB4-score, VCTE and the ELF-test. A blood sample will be stored for additional biomarker testing. Based on predefined cut-offs for the FIB4-score and liver stiffness measurement (LSM) (measured using VCTE), participants will be classified as being at low or high risk of advanced (≥F3)fibrosis (see figure 1). The ELF-test will be analysed in bulk and will thus not be used for risk assessment. Participants classified at low risk will remain under the care of their treating specialist. Participants classified at high risk of advanced (≥F3) fibrosis will be referred to a hepatologist. Read-outs of the electronic health records (EHR) of all participants will be performed at 24 months after inclusion in the study, an dat six months for those classified at high risk. Read-outs will be performed to assess the correctness of the risk assessment and subsequent referral to the hepatologist.

The three different sequential, two-tiered care path algorithms will be evaluated upon completion of the study. The diagnostic accuracy, defined as sensitivity, specificity, predictive values and AUROCs, of the three different care path algorithms will be calculated. The diagnostic performance will be expressed as the percentage of correct referrals and the percentage of unnecessary referrals of the different care path algorithms and the individual non-invasive tests, compared to regular care.

Study population:

The study population consists of adults (≥ 18 years old) who are suspected by their treating specialist to suffer from a severe stage of NAFLD-fibrosis. Exclusion criteria are, most notably, a previous diagnosis of advanced (≥F3) fibrosis, any other known chronic liver disease, use of drugs that may cause drug-induced steatosis, and present excessive alcohol use. The aim is to include 200 patients in analyses in total, of which 100 will be referred using the NLA2 study and 100 through regular care. The latter group will form the prospective comparator arm. This necessitates a 50% adherence rate of participating hospitals.

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients will be recruited from three different academic medical centres in the Netherlands, namely Radboudumc, LUMC and Amsterdam UMC. Patients who are suspected of underlying severe NAFLD-fibrosis by their treating physician are eligible for inclusion in the study. This suspection will most often arise because of risk factors as obesity, diabetes type 2, hypercholesterolemia or metabolic syndrome, or proven heaptic steatosis because of an conventional ultrasound. Patients are referred from hospital specialists

Description

Inclusion Criteria:

  • Age ≥ 18 years;
  • Suspected by treating physician to suffer from a severe stage of NAFLD-fibrosis.

Exclusion Criteria:

  • Previous diagnosis of advanced (≥F3) liver fibrosis;
  • Any other known chronic liver disease (alcoholic steatohepatitis, hepatitis B, hepatitis C, autoimmune hepatitis, hemochromatosis, Wilsons disease, alpha-1-antitrypsin deficiency);
  • Drugs that may cause drug-induced hepatic steatosis, (table provided elsewhere)
  • Present excessive alcohol use, defined as > 2 units/day for women and > 3 units/day for men;
  • A psychiatric, addictive or any other disorder that compromises the subject's ability to understand the study content and to give written informed consent for the participation in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Prospective care path arm

Participants who enter the care path will make up the prospective care path arm.

In patients entering the care path three diagnostic tests for liver fibrosis will be performed. FIB4-score, Vibration controlled transient elastography and Enhanced Liver Fibrosis test
Diagnostic test: FIB4-score
A score which estimates the risk for advanced liver fibrosis, based on: age, ALT, AST and thrombocytes
Diagnostic test: Vibration controlled transient elastography
VCTE measures the speed of a mechanically generated shear wave across the liver to derive a liver stiffness measurement (LSM), a marker of hepatic fibrosis
Other Names:
  • VCTE
Diagnostic test: Enhanced Liver Fibrosis test
The ELF-test is a non-invasive blood test that measures three direct markers of liver fibrosis: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1).
Other Names:
  • ELF-test
Prospective arm of 'regular care'
Patients who are referred to the hepatologist in participating centers during the study period without using the care path (e.g. because of altered liver function tests for instance), will be the prospective 'regular care' arm
Retrospective arm of 'regular care'
The investigators will do an data extraction of the electronic health records of patients referred to the hepatologist in the five years prior to the study. They will make up the retrospective comparative arm of regular care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diagnostic accuracy of the three different care paths to detect advanced fibrosis.
Time Frame: The time frame is based on the time between the study visit and the subsequent read-outs of the EHR, up to 24 months later
The diagnostic accuracy of the three different sequential care path algorithms to detect underlying advanced (≥F3) liver fibrosis, assessed using sensitivity, specificity, predictive values and area under the receiver characteristics (AUROC) curve
The time frame is based on the time between the study visit and the subsequent read-outs of the EHR, up to 24 months later
Diagnostic performance of the three different care paths to increase correct and decrease incorrect referrals.
Time Frame: The time frame is based on the time between the study visit and the subsequent read-outs of the EHR, up to 24 months later
The diagnostic performance of the three different sequential care path algorithms, defined as the increase in correct and the decrease in unnecessary referrals when using these care paths to detect underlying advanced (≥F3) NAFLD-fibrosis compared to regular care.
The time frame is based on the time between the study visit and the subsequent read-outs of the EHR, up to 24 months later

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cost effectiveness of the different diagnostic modalities/care path algorithms
Time Frame: The time frame is based on the time between the study visit and the subsequent read-outs of the EHR, up to 24 months later.
The cost effectiveness of the different diagnostic modalities/care path algorithms compared to each other and to regular care.
The time frame is based on the time between the study visit and the subsequent read-outs of the EHR, up to 24 months later.
Number of patients coded for NAFLD before and after the study
Time Frame: through study completion, an average of 1 year
Number of patients coded for NAFLD by physicians before and after initiation of the NLA2 study (measure of awareness)
through study completion, an average of 1 year
The diagnostic accuracy of the FIB4-score for detecting advanced fibrosis
Time Frame: The time frame is based on the time between the study visit and the subsequent read-outs of the EHR, up to 24 months later.
The diagnostic accuracy of the FIB4-score for detecting underlying advanced (≥F3) liver fibrosis, using sensitivity, specificity, predictive values and AUROC-curves;
The time frame is based on the time between the study visit and the subsequent read-outs of the EHR, up to 24 months later.
The diagnostic accuracy of the ELF-test for detecting advanced fibrosis
Time Frame: The time frame is based on the time between the study visit and the subsequent read-outs of the EHR, up to 24 months later.
The diagnostic accuracy of the ELF-test for detecting underlying advanced (≥F3) liver fibrosis, using sensitivity, specificity, predictive values and AUROC-curves;
The time frame is based on the time between the study visit and the subsequent read-outs of the EHR, up to 24 months later.
The diagnostic accuracy of VCTE for detecting advanced fibrosis
Time Frame: The time frame is based on the time between the study visit and the subsequent read-outs of the EHR, up to 24 months later.
The diagnostic accuracy of VCTE for detecting underlying advanced (≥F3) liver fibrosis, using sensitivity, specificity, predictive values and AUROC-curves;
The time frame is based on the time between the study visit and the subsequent read-outs of the EHR, up to 24 months later.
Diagnostic performance of the FIB4-score to increase correct and decrease incorrect referrals.
Time Frame: The time frame is based on the time between the study visit and the subsequent read-outs of the EHR, up to 24 months later.
The diagnostic performance of the FIB4-score, defined as the increase in correct and the decrease in unnecessary referrals when using this test to detect underlying advanced (≥F3) NAFLD-fibrosis compared to regular care.
The time frame is based on the time between the study visit and the subsequent read-outs of the EHR, up to 24 months later.
Diagnostic performance of VCTE to increase correct and decrease incorrect referrals.
Time Frame: The time frame is based on the time between the study visit and the subsequent read-outs of the EHR, up to 24 months later.
The diagnostic performance of VCTE, defined as the increase in correct and the decrease in unnecessary referrals when using this test to detect underlying advanced (≥F3) NAFLD-fibrosis compared to regular care.
The time frame is based on the time between the study visit and the subsequent read-outs of the EHR, up to 24 months later.
Diagnostic performance of the ELF-test to increase correct and decrease incorrect referrals.
Time Frame: The time frame is based on the time between the study visit and the subsequent read-outs of the EHR, up to 24 months later.
The diagnostic performance of the ELF-test, defined as the increase in correct and the decrease in unnecessary referrals when using this test to detect underlying advanced (≥F3) NAFLD-fibrosis compared to regular care.
The time frame is based on the time between the study visit and the subsequent read-outs of the EHR, up to 24 months later.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Collaborators

Radboud University Medical Center
Leiden University Medical Center
Maag Lever Darm Stichting

Investigators

  • Principal Investigator: Onno Holleboom, MD PhD, Amsterdam UMC, location AMC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 1, 2022

Primary Completion (ANTICIPATED)

September 30, 2025

Study Completion (ANTICIPATED)

March 30, 2026

Study Registration Dates

First Submitted

October 19, 2022

First Submitted That Met QC Criteria

February 1, 2023

First Posted (ACTUAL)

February 3, 2023

Study Record Updates

Last Update Posted (ACTUAL)

February 3, 2023

Last Update Submitted That Met QC Criteria

February 1, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NL81357.018.22

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Non-Alcoholic Fatty Liver Disease

Clinical Trials on FIB4-score

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe